SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

This study is testing a drug combination that includes SHR-A1811 (an antibody-drug conjugate targeting HER2) for women with recurrent or metastatic cervical cancer that has come back or spread after prior treatment. **You may be eligible if...** - You are a woman aged 18–75 with recurrent or metastatic cervical cancer - Your vital organ function (heart, liver, kidneys) is adequate - You have a life expectancy of at least 12 weeks - You have a negative pregnancy test and agree to use contraception during and after treatment **You may NOT be eligible if...** - You have a current or prior other cancer diagnosis - You have severe bone damage from bone metastases - You have active autoimmune disease - You have active tuberculosis - You have poorly controlled heart disease or blood clots in the past 6 months - You have had a bowel obstruction recently or in the past 6 months Talk to your doctor to see if this trial is right for you.